NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Has Average Target Price of $7.33

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been assigned an average rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $7.33.

A number of equities research analysts have recently weighed in on the company. Maxim Group set a $5.00 target price on NeuroOne Medical Technologies and gave the stock a “buy” rating in a research report on Friday, August 14th. Weiss Ratings lowered NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st.

NeuroOne Medical Technologies Trading Down 7.6%

Shares of NeuroOne Medical Technologies stock opened at $0.96 on Tuesday. The company’s fifty day simple moving average is $1.50 and its 200-day simple moving average is $2.79. NeuroOne Medical Technologies has a 1 year low of $0.95 and a 1 year high of $6.12. The company has a market cap of $8.75 million, a price-to-earnings ratio of -1.01 and a beta of 0.77.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its earnings results on Thursday, August 13th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 128.12%. The firm had revenue of $1.97 million during the quarter, compared to analyst estimates of $2.17 million. As a group, research analysts forecast that NeuroOne Medical Technologies will post -0.39 earnings per share for the current fiscal year.

Insider Transactions at NeuroOne Medical Technologies

In related news, insider David Wambeke acquired 33,333 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was bought at an average price of $2.01 per share, with a total value of $66,999.33. Following the acquisition, the insider owned 199,999 shares in the company, valued at $401,997.99. This represents a 20.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

A number of hedge funds have recently modified their holdings of NMTC. Susquehanna International Group LLP acquired a new position in shares of NeuroOne Medical Technologies during the 2nd quarter valued at $41,000. BlackRock Inc. purchased a new position in NeuroOne Medical Technologies in the second quarter valued at about $76,000. Finally, Bard Associates Inc. bought a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth $929,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation is a medical device company focused on developing and commercializing technologies for recording, monitoring, and treating neurological disorders. Its products are designed for use by neurosurgeons and neurologists in procedures involving the brain and nervous system, including the diagnosis and treatment of epilepsy and other neurological conditions.

The company’s product portfolio includes the Evo cortical and stereoelectroencephalography (sEEG) electrode systems, which are used to record electrical activity in the brain.